Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model

Molecular Nutrition and Food Research

Volumn 59, Issue 3, 2015, Pages 413-423

  Andrade, Juan E ^a   Ju, Young H ^b   Baker, Chandra ^b   Doerge, Daniel R ^c   Helferich, William G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Athymic mice; Breast cancer progression; Genistein; MCF 7; Soy protein isolate

Indexed keywords

MUS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; GENISTEIN; SOYBEAN PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GENISTEIN; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SOYBEAN PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923848921     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300780     Document Type: Article

References (53)

1. Barnes, S., The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat. Res. Biol. 2010, 8, 89-98.
2. Kuiper, G. G., Lemmen, J. G., Carlsson, B., Corton, J. C. et al., Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252-4263.
3. Jefferson, W. N., Williams, C. J., Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes. Reprod. Toxicol. 2011, 31, 272-279.
4. Branca, F., Lorenzetti, S., Health effects of phytoestrogens. Forum. Nutr. 2005, 57, 100-111.
5. Patisaul, H. B., Jefferson, W., The pros and cons of phytoestrogens. Front. Neuroendocrinol. 2010, 31, 400-419.
6. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
7. Bouker, K. B., Hilakivi-Clarke, L., Genistein: does it prevent or promote breast cancer? Environ. Health Perspect. 2000, 108, 701-708.
8. Messina, M. J., Persky, V., Setchell, K. D., Barnes, S., Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer 1994, 21, 113-131.
9. Toniolo, P. G., Levitz, M., Zeleniuch-Jacquotte, A., Banerjee, S. et al., A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 1995, 87, 190-197.
10. Mokbel, K., Risk-reducing strategies for breast cancer-a review of recent literature. Int. J. Fertil. Womens Med. 2003, 48, 274-277.
11. Helferich, W. G., Andrade, J. E., Hoagland, M. S., Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008, 16, 219-226.
12. Johnston, S. R., Head, J., Pancholi, S., Detre, S. et al., Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 2003, 9, 524S-532S.
13. Osborne, C. K., Coronado, E. B., Robinson, J. P., Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 1987, 23, 1189-1196.
14. Ju, Y. H., Allred, C. D., Allred, K. F., Karko, K. L. et al., Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J. Nutr. 2001, 131, 2957-2962.
15. Ju, Y. H., Allred, K. F., Allred, C. D., Helferich, W. G., Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis. 2006, 27, 1292-1299.
16. Allred, C. D., Allred, K. F., Ju, Y. H., Goeppinger, T. S. et al., Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004, 25, 1649-1657.
17. Allred, C. D., Twaddle, N. C., Allred, K. F., Goeppinger, T. S. et al., Soy processing affects metabolism and disposition of dietary isoflavones in ovariectomized BALB/c mice. J. Agric. Food Chem. 2005, 53, 8542-8550.
18. Allred, C. D., Allred, K. F., Ju, Y. H., Virant, S. M. et al., Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001, 61, 5045-5050.
19. Van Patten, C. L., Olivotto, I. A., Chambers, G. K., Gelmon, K. A. et al., Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J. Clin. Oncol. 2002, 20, 1449-1455.
20. Ju, Y. H., Doerge, D. R., Allred, K. F., Allred, C. D. et al., Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002, 62, 2474-2477.
21. Ju, Y. H., Doerge, D. R., Woodling, K. A., Hartman, J. A. et al., Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008, 29, 2162-2168.
22. Du, M., Yang, X., Hartman, J. A., Cooke, P. S. et al., Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 2012, 33, 895-901.
23. Andrade, J. E., Twaddle, N. C., Helferich, W. G., Doerge, D. R., Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice. J. Agric. Food Chem. 2010, 58, 4529-4536.
24. Twaddle, N. C., Churchwell, M. I., Doerge, D. R., High-throughput quantification of soy isoflavones in human and rodent blood using liquid chromatography with electrospray mass spectrometry and tandem mass spectrometry detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 777, 139-145.
25. Naaz, A., Yellayi, S., Zakroczymski, M. A., Bunick, D. et al., The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003, 144, 3315-3320.
26. Hsieh, C. Y., Santell, R. C., Haslam, S. Z., Helferich, W. G., Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998, 58, 3833-3838.
27. Chuthapisith, S., Eremin, J. M., Eremin, O., Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (review). Oncol. Rep. 2008, 20, 699-703.
28. Clark, G. M., Osborne, C. K., McGuire, W. L., Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 1984, 2, 1102-9.
29. Harlan, L. C., Abrams, J., Warren, J. L., Clegg, L. et al., Adjuvant therapy for breast cancer: practice patterns of community physicians. J. Clin. Oncol. 2002, 20, 1809-1817.
30. Mayo Medical Laboratories, The pharmacogenetics of tamoxifen therapy. Mayo Reference Services Communiqué 2007, 32, 1; 7.
31. Fisher, B., Dignam, J., Bryant, J., DeCillis, A. et al., Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 1996, 88, 1529-1542.
32. Herman, M. E., Katzenellenbogen, B. S., Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 1994, 54, 5867-5874.
33. Berstein, L. M., Zheng, H., Yue, W., Wang, J. P. et al., New approaches to the understanding of tamoxifen action and resistance. Endocr. Relat. Cancer 2003, 10, 267-277.
34. Shim, W. S., Conaway, M., Masamura, S., Yue, W. et al., Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000, 141, 396-405.
35. Song, T. T., Hendrich, S., Murphy, P. A., Estrogenic activity of glycitein, a soy isoflavone. J. Agric. Food Chem. 1999, 47, 1607-1610.
36. Ju, Y. H., Fultz, J., Allred, K. F., Doerge, D. R. et al., Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006, 27, 856-863.
37. Saarinen, N. M., Power, K., Chen, J., Thompson, L. U., Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int. J. Cancer 2006, 119, 925-931.
38. Harbeck, N., Pegram, M. D., Ruschoff, J., Mobus, V., Targeted therapy in metastatic breast cancer: the HER2/neu oncogene. Breast Care (Basel) 2010, 5, 3-7.
39. Dowsett, M., Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 2001, 8, 191-195.
40. Sihto, H., Lundin, J., Lehtimaki, T., Sarlomo-Rikala, M. et al., Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin. Cancer Res. 2008, 14, 4103-4110.
41. Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M. et al., Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer. 2001, 8, 175-182.
42. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M. et al., Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 1993, 26, 237-246.
43. Bayliss, J., Hilger, A., Vishnu, P., Diehl, K. et al., Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin. Cancer Res. 2007, 13, 7029-7036.
44. Bobustuc, G. C., Smith, J. S., Maddipatla, S., Jeudy, S. et al., MGMT inhibition restores ERalpha functional sensitivity to antiestrogen therapy. Mol. Med. 2012, 18, 913-929.
45. Fan, P., Wang, J., Santen, R. J., Yue, W., Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 2007, 67, 1352-1360.
46. Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V. et al., Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl. Cancer Inst. 1991, 83, 1477-1482.
47. Wu, A. H., Yu, M. C., Tseng, C. C., Pike, M. C., Epidemiology of soy exposures and breast cancer risk. Br. J. Cancer 2008, 98, 9-14.
48. Shu, X. O., Zheng, Y., Cai, H., Gu, K. et al., Soy food intake and breast cancer survival. JAMA 2009, 302, 2437-2443.
49. Setchell, K. D., Zimmer-Nechemias, L., Cai, J., Heubi, J. E., Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 1997, 350, 23-27.
50. Messina, M., A brief historical overview of the past two decades of soy and isoflavone research. J. Nutr. 2010, 140, 1350S-1354S.
51. Setchell, K. D., Absorption and metabolism of soy isoflavones-from food to dietary supplements and adults to infants. J. Nutr. 2000, 130, 654S-655S.
52. United Soybean Board, 18th Annual Consumer Attitudes Report about Nutrition: Insights into nutrition, health and soyfoods. 2011 Edition, 12 p.
53. Maskarinec, G., Murphy, S., Shumay, D. M., Kakai, H., Dietary changes among cancer survivors. Eur. J. Cancer Care. (Engl) 2001, 10, 12-20.